{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T10:58:32Z","timestamp":1774263512072,"version":"3.50.1"},"reference-count":82,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,11,30]],"date-time":"2020-11-30T00:00:00Z","timestamp":1606694400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,11,30]],"date-time":"2020-11-30T00:00:00Z","timestamp":1606694400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Clin Microbiol Antimicrob"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>At the time of writing, the SARS-CoV-2 virus has infected more than 49 million people causing more than 1.2 million deaths worldwide since its emergence from Wuhan, China in December 2019. Vaccine development against SARS-CoV-2 has drawn the global attention in order to stop the spread of the virus, with more than 10 vaccines being tested in phase III clinical trials, as of November 2020. However, critical to vaccine development is consideration of the immunological response elicited as well as biological features of the vaccine and both need to be evaluated thoroughly. Tuberculosis is also a major infectious respiratory disease of worldwide prevalence and the vaccine development for tuberculosis has been ongoing for decades. In this review, we highlight some of the common features, challenges and complications in tuberculosis vaccine development, which may also be relevant for, and inform, COVID-19 vaccine development.<\/jats:p>","DOI":"10.1186\/s12941-020-00402-x","type":"journal-article","created":{"date-parts":[[2020,11,30]],"date-time":"2020-11-30T13:02:52Z","timestamp":1606741372000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["COVID-19 vaccine development: What lessons can we learn from TB?"],"prefix":"10.1186","volume":"19","author":[{"given":"Hussain A.","family":"Safar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abu Salim","family":"Mustafa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy D.","family":"McHugh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,11,30]]},"reference":[{"key":"402_CR1","unstructured":"Coronavirus. Who.int. 2020. https:\/\/www.who.int\/emergencies\/diseases\/novel-coronavirus-2019. Accessed 12 Nov 2020."},{"issue":"10181","key":"402_CR2","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.1016\/S0140-6736(19)30308-3","volume":"393","author":"J Furin","year":"2019","unstructured":"Furin J, Cox J, Pai M. Tuberculosis. Lancet. 2019;393(10181):1642\u201356.","journal-title":"Lancet."},{"issue":"5","key":"402_CR3","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1631\/jzus.B2000083","volume":"21","author":"Y Shi","year":"2020","unstructured":"Shi Y, Wang G, Cai X, Deng J, Zheng L, Zhu H, et al. An overview of COVID-19. J Zhejiang Univ Sci B. 2020;21(5):343\u201360.","journal-title":"J Zhejiang Univ Sci B."},{"key":"402_CR4","unstructured":"Tuberculosis (TB). Who.int. 2020. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/tuberculosis. Accessed 22 June 2020."},{"issue":"1645","key":"402_CR5","doi-asserted-by":"publisher","first-page":"20130433","DOI":"10.1098\/rstb.2013.0433","volume":"369","author":"B Greenwood","year":"2014","unstructured":"Greenwood B. The contribution of vaccination to global health: past, present and future. Phil Trans Royal Soc B. 2014;369(1645):20130433.","journal-title":"Phil Trans Royal Soc B"},{"key":"402_CR6","doi-asserted-by":"crossref","unstructured":"Huang Q, Herrmann A. Fast assessment of human receptor-binding capability of 2019 novel coronavirus (2019-nCoV). bioRxiv. 2020.","DOI":"10.1101\/2020.02.01.930537"},{"issue":"7798","key":"402_CR7","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","volume":"579","author":"P Zhou","year":"2020","unstructured":"Zhou P, Yang X, Wang X, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579(7798):270\u20133.","journal-title":"Nature"},{"issue":"10223","key":"402_CR8","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","volume":"395","author":"C Huang","year":"2020","unstructured":"Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497\u2013506.","journal-title":"Lancet."},{"issue":"1","key":"402_CR9","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1002\/JLB.3COVR0520-272R","volume":"108","author":"J Wang","year":"2020","unstructured":"Wang J, Jiang M, Chen X, Montaner L. Cytokine storm and leukocyte changes in mild versus severe SARS-CoV-2 infection: review of 3939 COVID-19 patients in China and emerging pathogenesis and therapy concepts. J Leukoc Biol. 2020;108(1):17\u201341.","journal-title":"J Leukoc Biol"},{"issue":"9","key":"402_CR10","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1002\/jmv.25727","volume":"92","author":"Z Li","year":"2020","unstructured":"Li Z, Yi Y, Luo X, Xiong N, Liu Y, Li S, et al. Development and Clinical Application of A Rapid IgM-IgG Combined Antibody Test for SARS-CoV-2 Infection Diagnosis. J Med Virol. 2020;92(9):1518\u201324.","journal-title":"J Med Virol"},{"issue":"6","key":"402_CR11","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1038\/s41577-020-0311-8","volume":"20","author":"M Tay","year":"2020","unstructured":"Tay M, Poh C, R\u00e9nia L, MacAry P, Ng L. The trinity of COVID-19: immunity, inflammation and intervention. Nat Rev Immunol. 2020;20(6):363\u201374.","journal-title":"Nat Rev Immunol"},{"issue":"5","key":"402_CR12","doi-asserted-by":"publisher","first-page":"833","DOI":"10.3390\/v4050833","volume":"4","author":"T Cecere","year":"2012","unstructured":"Cecere T, Todd S, LeRoith T. Regulatory T cells in arterivirus and coronavirus infections: do they protect against disease or enhance it? Viruses. 2012;4(5):833\u201346.","journal-title":"Viruses."},{"issue":"4","key":"402_CR13","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1002\/jmv.25685","volume":"92","author":"G Li","year":"2020","unstructured":"Li G, Fan Y, Lai Y, Han T, Li Z, Zhou P, et al. Coronavirus infections and immune responses. J Med Virol. 2020;92(4):424\u201332.","journal-title":"J Med Virol"},{"issue":"18","key":"402_CR14","first-page":"30004","volume":"S1044\u20135323","author":"S Cole","year":"1998","unstructured":"Cole S, Brosch R, Parkhill J, Garnier T, Churcher C, Harris D. Deciphering the biology of Mycobacterium tuberculosis antigens as correlates of infection, disease, immunity and targets for vaccination. Semin Immunol. 1998;S1044\u20135323(18):30004\u20136.","journal-title":"Semin Immunol"},{"key":"402_CR15","doi-asserted-by":"publisher","first-page":"2","DOI":"10.4172\/2161-1068.1000129","volume":"3","author":"A Mustafa","year":"2013","unstructured":"Mustafa A. Diagnostic and vaccine potentials of ESAT-6 family proteins encoded by M. tuberculosis genomic regions absent in M. bovis BCG. J Mycobac Dis. 2013;3:2.","journal-title":"J Mycobac Dis."},{"issue":"5","key":"402_CR16","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1128\/JB.178.5.1274-1282.1996","volume":"178","author":"G Mahairas","year":"1996","unstructured":"Mahairas G, Sabo P, Hickey M, Singh D, Stover C. Molecular analysis of genetic differences between Mycobacterium bovis BCG and virulent M. bovis. J Bacteriol. 1996;178(5):1274\u201382.","journal-title":"J Bacteriol"},{"issue":"5419","key":"402_CR17","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1126\/science.284.5419.1520","volume":"284","author":"M Behr","year":"1999","unstructured":"Behr M, Wilson M, Gill W, Salamon H, Schoolnik G, Rane S, et al. Comparative genomics of BCG vaccines by whole-genome DNA microarray. Science. 1999;284(5419):1520\u20133.","journal-title":"Science"},{"issue":"3","key":"402_CR18","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1046\/j.1365-2958.1999.01383.x","volume":"32","author":"S Gordon","year":"1999","unstructured":"Gordon S, Brosch R, Billault A, Garnier T, Eiglmeier K, Cole S. Identification of variable regions in the genomes of tubercle bacilli using bacterial artificial chromosome arrays. Mol Microbiol. 1999;32(3):643\u201355.","journal-title":"Mol Microbiol"},{"key":"402_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2015\/527395","volume":"2015","author":"M Niki","year":"2015","unstructured":"Niki M, Suzukawa M, Akashi S, Nagai H, Ohta K, Inoue M, et al. Evaluation of humoral immunity to Mycobacterium tuberculosis-specific antigens for correlation with clinical status and effective vaccine development. J Immunol Res. 2015;2015:1\u201313.","journal-title":"J Immunol Res."},{"issue":"1","key":"402_CR20","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1080\/22221751.2020.1719902","volume":"9","author":"J Chan","year":"2020","unstructured":"Chan J, Kok K, Zhu Z, Chu H, To K, Yuan S, et al. Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan. Emerg Microbes Infect. 2020;9(1):221\u201336.","journal-title":"Emerg Microbes Infect."},{"issue":"10224","key":"402_CR21","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/S0140-6736(20)30251-8","volume":"395","author":"R Lu","year":"2020","unstructured":"Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020;395(10224):565\u201374.","journal-title":"Lancet"},{"key":"402_CR22","doi-asserted-by":"crossref","unstructured":"Jaimes J, Andr\u00e9 N, Millet J, Whittaker G. Structural modeling of 2019-novel coronavirus (nCoV) spike protein reveals a proteolytically-sensitive activation loop as a distinguishing feature compared to SARS-CoV and related SARS-like coronaviruses. bioRxiv. 2020.","DOI":"10.1101\/2020.02.10.942185"},{"key":"402_CR23","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1038\/s41586-020-2380-z","volume":"584","author":"B Ju","year":"2020","unstructured":"Ju B, Zhang Q, Ge J, Wang R, Sun J, Ge X, et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. 2020;584:115\u20139.","journal-title":"Nature"},{"key":"402_CR24","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.addr.2015.11.012","volume":"102","author":"E Agger","year":"2016","unstructured":"Agger E. Novel adjuvant formulations for delivery of anti-tuberculosis vaccine candidates. Adv Drug Deliv Rev. 2016;102:73\u201382.","journal-title":"Adv Drug Deliv Rev"},{"key":"402_CR25","doi-asserted-by":"publisher","first-page":"407","DOI":"10.3389\/fimmu.2017.00407","volume":"8","author":"J Moliva","year":"2017","unstructured":"Moliva J, Turner J, Torrelles J. Immune responses to Bacillus Calmette-Gu\u00e9rin vaccination: why do they fail to protect against Mycobacterium tuberculosis? Front Immunol. 2017;8:407.","journal-title":"Front Immunol."},{"issue":"2","key":"402_CR26","doi-asserted-by":"publisher","first-page":"e0228381","DOI":"10.1371\/journal.pone.0228381","volume":"15","author":"H Safar","year":"2020","unstructured":"Safar H, Mustafa A, Amoudy A, El-Hashim A. The effect of adjuvants and delivery systems on Th1, Th2, Th17 and Treg cytokine responses in mice immunized with Mycobacterium tuberculosis-specific proteins. PLoS ONE. 2020;15(2):e0228381.","journal-title":"PLoS ONE"},{"issue":"1","key":"402_CR27","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.ijmyco.2015.09.006","volume":"5","author":"N Kadir","year":"2016","unstructured":"Kadir N, Sarmiento M, Acosta A, Norazmi M. Cellular and humoral immunogenicity of recombinant Mycobacterium smegmatis expressing Ag85B epitopes in mice. Int J Mycobacteriol. 2016;5(1):7\u201313.","journal-title":"Int J Mycobacteriol."},{"key":"402_CR28","doi-asserted-by":"publisher","first-page":"226","DOI":"10.3389\/fcimb.2017.00226","volume":"7","author":"Z Xiang","year":"2017","unstructured":"Xiang Z, Sun R, Lin C, Chen F, Mai J, Liu Y, et al. Immunogenicity and protective efficacy of a fusion protein tuberculosis vaccine combining five Esx family proteins. Front Cell Infect Microbiol. 2017;7:226.","journal-title":"Front Cell Infect Microbiol."},{"issue":"8","key":"402_CR29","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1080\/08916934.2018.1546291","volume":"51","author":"Y Liang","year":"2018","unstructured":"Liang Y, Zhao Y, Bai X, Xiao L, Yang Y, Zhang J, et al. Immunotherapeutic effects of Mycobacterium tuberculosis rv3407 DNA vaccine in mice. Autoimmunity. 2018;51(8):417\u201322.","journal-title":"Autoimmunity."},{"issue":"7","key":"402_CR30","doi-asserted-by":"publisher","first-page":"e00014","DOI":"10.1128\/IAI.00014-18","volume":"86","author":"E Stylianou","year":"2018","unstructured":"Stylianou E, Harrington-Kandt R, Beglov J, Bull N, Pinpathomrat N, Swarbrick G, et al. Identification and evaluation of novel protective antigens for the development of a candidate tuberculosis subunit vaccine. Infect Immun. 2018;86(7):e00014\u20138.","journal-title":"Infect Immun"},{"key":"402_CR31","doi-asserted-by":"crossref","unstructured":"Hokey D, O\u2019Dee D, Graves A, Douoguih M, Pau M, Versteege I et al. Heterologous prime-boost with Ad35\/AERAS-402 and MVA85A elicits potent CD8\u2009+\u2009T cell immune responses in a phase I clinical trial (VAC7P.969). J Immunol. 2014;192 (1 Supplement)(141.14).","DOI":"10.4049\/jimmunol.192.Supp.141.14"},{"issue":"205","key":"402_CR32","doi-asserted-by":"publisher","first-page":"205ra134","DOI":"10.1126\/scitranslmed.3006843","volume":"5","author":"F Smaill","year":"2013","unstructured":"Smaill F, Jeyanathan M, Smieja M, Medina M, Thanthrige-Don N, Zganiacz A, et al. A human type 5 adenovirus-based tuberculosis vaccine induces robust T cell responses in humans despite preexisting anti-adenovirus immunity. Sci Transl Med. 2013;5(205):205ra134.","journal-title":"Sci Transl Med."},{"issue":"17","key":"402_CR33","doi-asserted-by":"publisher","first-page":"9490","DOI":"10.1073\/pnas.2004168117","volume":"117","author":"K Duan","year":"2020","unstructured":"Duan K, Liu B, Li C, Zhang H, Yu T, Qu J, et al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc Natl Acad Sci USA. 2020;117(17):9490\u20136.","journal-title":"Proc Natl Acad Sci USA."},{"key":"402_CR34","doi-asserted-by":"publisher","first-page":"956","DOI":"10.3389\/fimmu.2019.00956","volume":"10","author":"M Slifka","year":"2019","unstructured":"Slifka M, Amanna I. Role of multivalency and antigenic threshold in generating protective antibody responses. Font Immunol. 2019;10:956.","journal-title":"Font Immunol."},{"key":"402_CR35","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.3389\/fimmu.2019.01317","volume":"10","author":"R Tanner","year":"2019","unstructured":"Tanner R, Villarreal-Ramos B, Vordermeier H, McShane H. The humoral immune response to BCG vaccination. Front Immunol. 2019;10:1317.","journal-title":"Front Immunol."},{"issue":"8986","key":"402_CR36","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1016\/S0140-6736(95)92348-9","volume":"346","author":"P Fine","year":"1995","unstructured":"Fine P. Variation in protection by BCG: implications of and for heterologous immunity. Lancet. 1995;346(8986):1339\u201345.","journal-title":"Lancet"},{"issue":"8","key":"402_CR37","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1038\/nrmicro1211","volume":"3","author":"P Andersen","year":"2005","unstructured":"Andersen P, Doherty T. The success and failure of BCG\u2014implications for a novel tuberculosis vaccine. Nat Rev Microbiol. 2005;3(8):656\u201362.","journal-title":"Nat Rev Microbiol"},{"issue":"8","key":"402_CR38","doi-asserted-by":"publisher","first-page":"e13525","DOI":"10.1111\/ijcp.13525","volume":"74","author":"M Becerra-Flores","year":"2020","unstructured":"Becerra-Flores M, Cardozo T. SARS-CoV-2 viral spike G614 mutation exhibits higher case fatality rate. Int J Clin Pract. 2020;74(8):e13525.","journal-title":"Int J Clin Pract"},{"key":"402_CR39","doi-asserted-by":"crossref","unstructured":"Al-Mulla F, Mohammad A, Al Madhoun A, Haddad D, Ali H, Eaaswarkhanth M et al. A comprehensive germline variant and expression analyses of ACE2, TMPRSS2 and SARS-CoV-2 activator FURIN genes from the Middle East: Combating SARS-CoV-2 with precision medicine. bioRxiv. 2020.","DOI":"10.1101\/2020.05.16.099176"},{"key":"402_CR40","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.ijid.2016.10.018","volume":"56","author":"S Kaufmann","year":"2017","unstructured":"Kaufmann S, Weiner J, von Reyn C. Novel approaches to tuberculosis vaccine development. Int J Infect Dis. 2017;56:263\u20137.","journal-title":"Int J Infect Dis."},{"key":"402_CR41","unstructured":"A Study to evaluate safety and immunogenicity of AERAS-402-full text view-ClinicalTrials.gov. Clinicaltrials.gov. 2020. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01378312. Accessed 19 June 2020"},{"issue":"4","key":"402_CR42","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1093\/cid\/cix834","volume":"66","author":"E Nemes","year":"2017","unstructured":"Nemes E, Hesseling A, Tameris M, Mauff K, Downing K, Mulenga H, et al. Safety and immunogenicity of newborn MVA85A vaccination and selective, delayed Bacille Calmette-Guerin for infants of human immunodeficiency virus-infected mothers: a phase 2 randomized, Controlled Trial. Clin Infect Dis. 2017;66(4):554\u201363.","journal-title":"Clin Infect Dis."},{"issue":"4","key":"402_CR43","doi-asserted-by":"publisher","first-page":"166","DOI":"10.3390\/vaccines7040166","volume":"7","author":"D Vasina","year":"2019","unstructured":"Vasina D, Kleymenov D, Manuylov V, Mazunina E, Koptev E, Tukhovskaya E, et al. First-in-human trials of GamTBvac, a recombinant subunit tuberculosis vaccine candidate: safety and immunogenicity assessment. Vaccines. 2019;7(4):166.","journal-title":"Vaccines."},{"issue":"6","key":"402_CR44","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/j.jmii.2014.03.005","volume":"48","author":"J Lu","year":"2015","unstructured":"Lu J, Chen B, Wang G, Fu L, Shen X, Su C, et al. Recombinant tuberculosis vaccine AEC\/BC02 induces antigen-specific cellular responses in mice and protects guinea pigs in a model of latent infection. J Microbiol Immunol Infect. 2015;48(6):597\u2013603.","journal-title":"J Microbiol Immunol Infect"},{"issue":"1","key":"402_CR45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41541-018-0057-5","volume":"3","author":"R Coler","year":"2018","unstructured":"Coler R, Day T, Ellis R, Piazza F, Beckmann A, Vergara J, et al. The TLR-4 agonist adjuvant, GLA-SE, improves magnitude and quality of immune responses elicited by the ID93 tuberculosis vaccine: first-in-human trial. NPJ Vaccines. 2018;3(1):1\u20139.","journal-title":"NPJ Vaccines."},{"issue":"9","key":"402_CR46","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/S2213-2600(19)30251-6","volume":"7","author":"M Tameris","year":"2019","unstructured":"Tameris M, Mearns H, Penn-Nicholson A, Gregg Y, Bilek N, Mabwe S, et al. Live-attenuated Mycobacterium tuberculosis vaccine MTBVAC versus BCG in adults and neonates: a randomised controlled, double-blind dose-escalation trial. Lancet Respir Med. 2019;7(9):757\u201370.","journal-title":"Lancet Respir Med."},{"key":"402_CR47","unstructured":"Reactogenicity, Safety and Immunogenicity of a TB\/FLU-04L Tuberculosis Vaccine-full text view-ClinicalTrials.gov [Internet]. Clinicaltrials.gov. 2020. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02501421. Accessed 19 June 2020"},{"key":"402_CR48","unstructured":"Safety of RUTI\u00ae Vaccination in MDR-TB Patients-Full text view-ClinicalTrials.gov [Internet]. Clinicaltrials.gov. 2020. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02711735. Accessed 19 June 2020"},{"issue":"2","key":"402_CR49","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1164\/rccm.201802-0366OC","volume":"199","author":"S Suliman","year":"2019","unstructured":"Suliman S, Luabeya A, Geldenhuys H, Tameris M, Hoff S, Shi Z, et al. Dose optimization of H56:IC31 vaccine for tuberculosis-endemic populations. A double-blind, placebo-controlled, dose-selection trial. Am J Respir Crit Care Med. 2019;199(2):220\u201331.","journal-title":"Am J Respir Crit Care Med"},{"issue":"17","key":"402_CR50","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1056\/NEJMoa1803484","volume":"379","author":"O Van Der Meeren","year":"2018","unstructured":"Van Der Meeren O, Hatherill M, Nduba V, Wilkinson R, Muyoyeta M, Van Brakel E, et al. Phase 2b controlled trial of M72\/AS01E vaccine to prevent tuberculosis. N Engl J Med. 2018;379(17):1621\u201334.","journal-title":"N Engl J Med"},{"issue":"5","key":"402_CR51","doi-asserted-by":"publisher","first-page":"e0217091","DOI":"10.1371\/journal.pone.0217091","volume":"14","author":"T Masonou","year":"2019","unstructured":"Masonou T, Hokey D, Lahey T, Halliday A, Berrocal-Almanza L, Wieland-Alter W, et al. CD4+\u2009T cell cytokine responses to the DAR-901 booster vaccine in BCG-primed adults: a randomized, placebo-controlled trial. PLoS ONE. 2019;14(5):e0217091.","journal-title":"PLoS ONE"},{"issue":"2","key":"402_CR52","first-page":"e00439","volume":"24","author":"A Loxton","year":"2016","unstructured":"Loxton A, Knaul J, Grode L, Gutschmidt A, Meller C, Eisele B, et al. Safety and Immunogenicity of the recombinant Mycobacterium bovis BCG Vaccine VPM1002 in HIV-Unexposed Newborn Infants in South Africa. Clin Vaccine Immunol. 2016;24(2):e00439.","journal-title":"Clin Vaccine Immunol"},{"issue":"1","key":"402_CR53","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-016-0028-x","volume":"7","author":"S Sharma","year":"2017","unstructured":"Sharma S, Katoch K, Sarin R, Balambal R, Kumar Jain N, Patel N, et al. Efficacy and Safety of Mycobacterium indicus pranii as an adjunct therapy in Category II pulmonary tuberculosis in a randomized trial. Sci Rep. 2017;7(1):1\u20132.","journal-title":"Sci Rep."},{"key":"402_CR54","doi-asserted-by":"publisher","first-page":"100141","DOI":"10.1016\/j.jctube.2019.100141","volume":"18","author":"A Bourinbaiar","year":"2020","unstructured":"Bourinbaiar A, Batbold U, Efremenko Y, Sanjagdorj M, Butov D, Damdinpurev N, et al. Phase III, placebo-controlled, randomized, double-blind trial of tableted, therapeutic TB vaccine (V7) containing heat-killed M. vaccae administered daily for one month. J Clin Tuberc Other Mycobact Dis. 2020;18:100141.","journal-title":"J Clin Tuberc Other Mycobact Dis."},{"issue":"1","key":"402_CR55","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-019-13993-7","volume":"11","author":"T Smith","year":"2020","unstructured":"Smith T, Patel A, Ramos S, Elwood D, Zhu X, Yan J, et al. Immunogenicity of a DNA vaccine candidate for COVID-19. Nat Commun. 2020;11(1):1\u20133.","journal-title":"Nat Commun."},{"key":"402_CR56","unstructured":"Clinical Study of Recombinant Novel Coronavirus Vaccine-ClinicalTrials.gov [Internet]. Clinicaltrials.gov. 2020. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04466085. Accessed 26 Aug 2020."},{"key":"402_CR57","unstructured":"Study to Describe the Safety, Tolerability, Immunogenicity, and Potential Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Adults-Full Text View-ClinicalTrials.gov. Clinicaltrials.gov. 2020. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04368728. Accessed 26 Aug 2020."},{"key":"402_CR58","unstructured":"A Phase II Clinical Trial to Evaluate the Recombinant Vaccine for COVID-19 (Adenovirus Vector) (CTII-nCoV) \u2013 ClinicalTrials.gov. 2020. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04341389. Accessed 26 Aug 2020."},{"key":"402_CR59","unstructured":"A Study to Evaluate Efficacy, Safety, and Immunogenicity of mRNA-1273 Vaccine in Adults Aged 18 Years and Older to Prevent COVID-19-ClinicalTrials.gov. Clinicaltrials.gov. 2020. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04470427. Accessed 26 Aug 2020."},{"key":"402_CR60","unstructured":"A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-Mediated COVID-19 in Adult Participants (ENSEMBLE). \u2013 ClinicalTrials.gov. Clinicaltrials.gov. 2020. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04505722. Accessed 26 Aug 2020."},{"key":"402_CR61","unstructured":"A phase III study to investigate a vaccine against COVID-19. ISRCTN registry. 2020. http:\/\/www.isrctn.com\/ISRCTN89951424. Accessed 26 Aug 2020."},{"key":"402_CR62","unstructured":"Clinical Trial of Efficacy and Safety of Sinovac\u2019s Adsorbed COVID-19 (Inactivated) Vaccine in Healthcare Professionals (PROFISCOV)-ClinicalTrials.gov. Clinicaltrials.gov. 2020. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04456595. Accessed 26 Aug 2020."},{"key":"402_CR63","unstructured":"A Phase III clinical trial for inactivated novel coronavirus pneumonia (COVID-19) vaccine (Vero cells)\u2013Chictr.org [Internet]. Chictr.org. 2020. http:\/\/www.chictr.org.cn\/showprojen.aspx?proj=56651. Accessed 26 Aug 2020"},{"issue":"9","key":"402_CR64","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1136\/adc.2009.157537","volume":"95","author":"F Shann","year":"2010","unstructured":"Shann F. The non-specific effects of vaccines. Arch Dis Child. 2010;95(9):662\u20137.","journal-title":"Arch Dis Child"},{"issue":"7","key":"402_CR65","doi-asserted-by":"publisher","first-page":"e0180143","DOI":"10.1371\/journal.pone.0180143","volume":"12","author":"S Mukherjee","year":"2017","unstructured":"Mukherjee S, Subramaniam R, Chen H, Smith A, Keshava S, Shams H. Boosting efferocytosis in alveolar space using BCG vaccine to protect host against influenza pneumonia. PLoS ONE. 2017;12(7):e0180143.","journal-title":"PLoS ONE"},{"issue":"1","key":"402_CR66","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1111\/j.1525-1470.2012.01848.x","volume":"30","author":"A Salem","year":"2012","unstructured":"Salem A, Nofal A, Hosny D. Treatment of common and plane warts in children with topical viable Bacillus Calmette-Guerin. Pediatr Dermatol. 2012;30(1):60\u20133.","journal-title":"Pediatr Dermatol"},{"issue":"3","key":"402_CR67","doi-asserted-by":"publisher","first-page":"242","DOI":"10.2174\/1874467208666150716120945","volume":"9","author":"M Vasekar","year":"2016","unstructured":"Vasekar M, Degraff D, Joshi M. Immunotherapy in Bladder Cancer. Current Molecular Pharmacology. 2016;9(3):242\u201351.","journal-title":"Current Molecular Pharmacology."},{"key":"402_CR68","doi-asserted-by":"publisher","first-page":"970","DOI":"10.3389\/fimmu.2020.00970","volume":"11","author":"C Covi\u00e1n","year":"2020","unstructured":"Covi\u00e1n C, Retamal-D\u00edaz A, Bueno S, Kalergis A. Could BCG vaccination induce protective trained immunity for SARS-CoV-2? Front Immunol. 2020;11:970.","journal-title":"Front Immunol."},{"issue":"5","key":"402_CR69","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/j.aller.2020.05.002","volume":"48","author":"A Sharma","year":"2020","unstructured":"Sharma A, Batra G, Kumar M, Mishra A, Singla R, Singh A, et al. BCG as a game-changer to prevent the infection and severity of COVID-19 pandemic? Allergol Immunopathol. 2020;48(5):507\u201317.","journal-title":"Allergol Immunopathol"},{"key":"402_CR70","doi-asserted-by":"crossref","unstructured":"Miller A, Reandelar M, Fasciglione K, Roumenova V, Li Y, Otazu G. Correlation between universal BCG vaccination policy and reduced mortality for COVID-19. medRexiv. 2020.","DOI":"10.1101\/2020.03.24.20042937"},{"issue":"7","key":"402_CR71","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1111\/all.14344","volume":"75","author":"C Ozdemir","year":"2020","unstructured":"Ozdemir C, Kucuksezer U, Tamay Z. Is BCG vaccination affecting the spread and severity of COVID-19? Allergy. 2020;75(7):1824\u20137.","journal-title":"Allergy"},{"issue":"41","key":"402_CR72","doi-asserted-by":"publisher","first-page":"6352","DOI":"10.1016\/j.vaccine.2020.08.045","volume":"38","author":"Y Tomita","year":"2020","unstructured":"Tomita Y, Sato R, Ikeda T, Sakagami T. BCG vaccine may generate cross-reactive T cells against SARS-CoV-2: in silico analyses and a hypothesis. Vaccine. 2020;38(41):6352\u20136.","journal-title":"Vaccine."},{"issue":"2","key":"402_CR73","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1159\/000355628","volume":"6","author":"J Kleinnijenhuis","year":"2013","unstructured":"Kleinnijenhuis J, Quintin J, Preijers F, Benn C, Joosten L, Jacobs C, et al. Long-lasting effects of BCG vaccination on both heterologous Th1\/Th17 responses and innate trained immunity. J Innate Immun. 2013;6(2):152\u20138.","journal-title":"J Innate Immun."},{"key":"402_CR74","unstructured":"Search of: BCG | COVID-19-List Results-ClinicalTrials.gov. Clinicaltrials.gov. 2020. https:\/\/clinicaltrials.gov\/ct2\/results?cond=COVID-19&term=BCG&cntry=&state=&city=&dist=. Accessed 3 Nov 2020."},{"issue":"41","key":"402_CR75","doi-asserted-by":"publisher","first-page":"5470","DOI":"10.1016\/j.vaccine.2015.07.103","volume":"33","author":"A Venkataraman","year":"2015","unstructured":"Venkataraman A, Yusuff M, Liebeschuetz S, Riddell A, Prendergast A. Management and outcome of Bacille Calmette-Gu\u00e9rin vaccine adverse reactions. Vaccine. 2015;33(41):5470\u20134.","journal-title":"Vaccine."},{"key":"402_CR76","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.3389\/fimmu.2017.01134","volume":"8","author":"H Dockrell","year":"2017","unstructured":"Dockrell H, Smith S. What have we learnt about BCG vaccination in the last 20 years? Front Immunol. 2017;8:1134.","journal-title":"Front Immunol."},{"issue":"7","key":"402_CR77","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1086\/597304","volume":"199","author":"N Mansoor","year":"2009","unstructured":"Mansoor N, Scriba T, de Kock M, Tameris M, Abel B, Keyser A, et al. HIV-1 infection in infants severely impairs the immune response induced by Bacille Calmette-Gu\u00e9rin Vaccine. J Infect Dis. 2009;199(7):982\u201390.","journal-title":"J Infect Dis"},{"issue":"10","key":"402_CR78","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/S1473-3099(14)70845-X","volume":"14","author":"I Satti","year":"2014","unstructured":"Satti I, Meyer J, Harris S, Thomas Z, Griffiths K, Antrobus R, et al. Safety and immunogenicity of a candidate tuberculosis vaccine MVA85A delivered by aerosol in BCG-vaccinated healthy adults: a phase 1, double-blind, randomised controlled trial. Lancet Infect Dis. 2014;14(10):939\u201346.","journal-title":"Lancet Infect Dis."},{"issue":"6","key":"402_CR79","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1038\/mi.2015.29","volume":"8","author":"M Jeyanathan","year":"2015","unstructured":"Jeyanathan M, Thanthrige-Don N, Afkhami S, Lai R, Damjanovic D, Zganiacz A, et al. Novel chimpanzee adenovirus-vectored respiratory mucosal tuberculosis vaccine: overcoming local anti-human adenovirus immunity for potent TB protection. Mucosal Immunol. 2015;8(6):1373\u201387.","journal-title":"Mucosal Immunol"},{"issue":"6494","key":"402_CR80","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1126\/science.abb8923","volume":"368","author":"B Graham","year":"2020","unstructured":"Graham B. Rapid COVID-19 vaccine development. Science. 2020;368(6494):945\u20136.","journal-title":"Science"},{"issue":"1","key":"402_CR81","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/1743-422X-11-82","volume":"11","author":"M Yip","year":"2014","unstructured":"Yip M, Leung N, Cheung C, Li P, Lee H, Da\u00ebron M, et al. Antibody-dependent infection of human macrophages by severe acute respiratory syndrome coronavirus. Virol J. 2014;11(1):82.","journal-title":"Virol J."},{"issue":"4","key":"402_CR82","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/j.vaccine.2006.08.011","volume":"25","author":"Y Kam","year":"2007","unstructured":"Kam Y, Kien F, Roberts A, Cheung Y, Lamirande E, Vogel L, et al. Antibodies against trimeric S glycoprotein protect hamsters against SARS-CoV challenge despite their capacity to mediate Fc\u03b3RII-dependent entry into B cells in vitro. Vaccine. 2007;25(4):729\u201340.","journal-title":"Vaccine."}],"container-title":["Annals of Clinical Microbiology and Antimicrobials"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12941-020-00402-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12941-020-00402-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12941-020-00402-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,14]],"date-time":"2023-10-14T07:15:27Z","timestamp":1697267727000},"score":1,"resource":{"primary":{"URL":"https:\/\/ann-clinmicrob.biomedcentral.com\/articles\/10.1186\/s12941-020-00402-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,30]]},"references-count":82,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["402"],"URL":"https:\/\/doi.org\/10.1186\/s12941-020-00402-x","relation":{},"ISSN":["1476-0711"],"issn-type":[{"value":"1476-0711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,30]]},"assertion":[{"value":"1 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 November 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"56"}}